These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 27220961)

  • 1. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics.
    Haake SM; Li J; Bai Y; Kinose F; Fang B; Welsh EA; Zent R; Dhillon J; Pow-Sang JM; Chen YA; Koomen JM; Rathmell WK; Fishman M; Haura EB
    Clin Cancer Res; 2016 Nov; 22(22):5605-5616. PubMed ID: 27220961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
    Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
    Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
    Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
    BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib activates Axl signaling in renal cell cancer.
    van der Mijn JC; Broxterman HJ; Knol JC; Piersma SR; De Haas RR; Dekker H; Pham TV; Van Beusechem VW; Halmos B; Mier JW; Jiménez CR; Verheul HM
    Int J Cancer; 2016 Jun; 138(12):3002-10. PubMed ID: 26815723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters.
    Abe Y; Nagano M; Tada A; Adachi J; Tomonaga T
    J Proteome Res; 2017 Feb; 16(2):1077-1086. PubMed ID: 28152594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
    Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
    Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
    Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
    Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
    Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
    Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
    BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors.
    Simon AG; Esser LK; Ellinger J; Branchi V; Tolkach Y; Müller S; Ritter M; Kristiansen G; Muders MH; Mayr T; Toma MI
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2255-2265. PubMed ID: 32533404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
    Brenner W; Greber I; Gudejko-Thiel J; Beitz S; Schneider E; Walenta S; Peters K; Unger R; Thüroff JW
    Int J Oncol; 2008 May; 32(5):1125-31. PubMed ID: 18425341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
    Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
    Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways.
    Yan GR; Xiao CL; He GW; Yin XF; Chen NP; Cao Y; He QY
    Proteomics; 2010 Mar; 10(5):976-86. PubMed ID: 20049867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.